Petosemtamab plus Keytruda halved the risk of death versus Keytruda alone in first-line PD-L1-positive head and neck cancer, the first positive Phase 3 in that setting in several years, as Genmab races to replace Darzalex royalties.
Top stories
Newsletter
Pipeline, markets, policy, and science. Once a week.
Its $1.275 billion upfront commitment to a Phase 1 program puts the spotlight on oral peptide developers, including Entera as it approaches Phase 3 in osteoporosis.
An oversubscribed EUR 120M Series D sends an off-the-shelf cancer vaccine toward a prevention trial measured in colonoscopy results from dozens, not thousands, of patients.
Merck KGaA is paying $1.3 billion for a Phase 2 siRNA that has not started Phase 3, entering a polycythemia vera market the FDA opened with Takeda's weekly injection two months ago. The bet rests on quarterly dosing and durable hematocrit control.
In depth
Viatris is paying $1.65 billion for Pacira, roughly 2.2 times trailing revenue. The price only makes sense if you count EXPAREL's early 2030 licensed generic cliff and the four years of runway before it.
Read the storyIntellia's lonvo-z is on a priority-review track to March 10, 2027 with no advisory committee planned. The one-dose gene edit cut HAE attacks 87% in Phase 3, and the debate over permanence, competition, and price will happen largely out of view.
CSL is paying $355 million upfront for an antibody whose best evidence is a 26-patient interim readout. The deal prices claudin-1 biology, not proven data, across kidney and liver fibrosis.
The FDA granted accelerated approval to AstraZeneca’s camizestrant based on ctDNA resistance signals before radiographic progression, overruling a 6-3 advisory committee vote and betting on a new oncology paradigm.
Conjugating antisense oligonucleotides to transferrin receptor transport vehicles achieves fifty-fold deeper brain penetration, challenging the standard of invasive spinal punctures.
